Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 2/20 | 0.53 |
| ▸ | PLAU | P00749 | 2/20 | 0.53 |
| ▸ | ELANE | P08246 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | CASP6 | P55212 | 2/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186625 | 0.86 | MEN1 (0.58) | KEAP1NFE2L2TP53MEN1KMT2A | |
| SCHEMBL25347365 | 0.84 | ALKBH2 (0.61) | KEAP1NFE2L2TP53NPC1RAB9A | |
| SCHEMBL30729451 | 0.82 | ALDH1A1 (0.51) | KEAP1NFE2L2MEN1KMT2ANPC1 | |
| SCHEMBL224389 | 0.81 | HSP90AA1 (0.62) | KEAP1NFE2L2MEN1KMT2ANPC1 | |
| SCHEMBL22095038 | 0.80 | HPGDS (0.56) | KEAP1NFE2L2MEN1KMT2ANPC1 | |
| SCHEMBL26696761 | 0.79 | HSP90AA1 (0.48) | KEAP1NFE2L2MEN1KMT2ANPC1 | |
| SCHEMBL22633155 | 0.79 | KEAP1 (0.56) | KEAP1NFE2L2MEN1KMT2ANPC1 | |
| SCHEMBL21816235 | 0.78 | MEN1 (0.75) | KEAP1NFE2L2MEN1KMT2ANPC1 | |
| SCHEMBL31175282 | 0.78 | MEN1 (0.75) | KEAP1NFE2L2MEN1KMT2ANPC1 | |
| SCHEMBL21934939 | 0.77 | MEN1 (0.60) | KEAP1NFE2L2MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2016-10-20 | — | — | US | disclosed |
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2016-10-20 | — | — | US | disclosed |
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2016-10-20 | — | — | US | disclosed |
| EP-3076789-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | The Scripps Research Institute (US) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015084936-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2015084936-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304466-A1 | NOVEL COMPOUNDS AS JNK KINASE INHIBITORS | MAPK3, MAP3K3, MAP3K2 | KEAP1 353/4885NFE2L2 251/4885TP53 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.